M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Norikazu Masuda,Hiroko Bando,Takashi Yamanaka,Takayuki Kadoya,Masato Takahashi,Shigenori Nagai,Shoichiro Ohtani,Tomoyuki Aruga,Eiji Suzuki,Yuichiro Kikawa,Hiroyuki Yasojima,Hiroi Kasai,Hiroshi Ishiguro,Hidetaka Kawabata,Satoshi Morita,Hironori Haga,Tatsuki R. Kataoka,Ryuji Uozumi,Shinji Ohno,Masakazu Toi +19 more
TL;DR: In this paper, the clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients was investigated, and patients in group A (aged 60% and 40% respectively) indicated potential usefulness of patient stratification using HRD; pCR tended to be low in patients with HRD-negative tumors.
Journal ArticleDOI
Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
Yutaka Yamamoto,Hiroji Iwata,Naruto Taira,Norikazu Masuda,J. Takahashi,Tetsuhiro Yoshinami,Takayuki Ueno,Tatsuya Toyama,Takashi Yamanaka,Toshimi Takano,Masahiro Kashiwaba,Koichiro Tsugawa,Yoshie Hasegawa,Kenji Tamura,Hiroshi Tada,Fumikata Hara,Tomomi Fujisawa,Naoki Niikura,Shigehira Saji,Satoshi Morita,Masakazu Toi,Shinji Ohno +21 more
TL;DR: The PTC arm showed a trend towards better overall survival and duration of response, but similar objective response and health‐related quality of life, as well as the primary end‐point was investigator‐assessed progression‐free survival (PFS).
Journal ArticleDOI
Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial.
Osamu Miyake,Osamu Miyake,Kyoko Murata,Shiro Tanaka,Hiroshi Ishiguro,Masakazu Toi,Kazuo Tamura,Koji Kawakami +7 more
TL;DR: Pegfilgrastim reduced the costs incurred for both drugs and hospitalization for AEs as well as FN, although the total medical cost during the chemotherapy increased.
Journal ArticleDOI
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Yutaka Yamamoto,Hiroji Iwata,Takayuki Ueno,Naruto Taira,Masahiro Kashiwaba,Masato Takahashi,Hiroshi Tada,Koichiro Tsugawa,Tatsuya Toyama,Naoki Niikura,Fumikata Hara,Tomomi Fujisawa,Tetsuhiro Yoshinami,Shigehira Saji,Toshimi Takano,Norikazu Masuda,Satoshi Morita,Masakazu Toi,Shinji Ohno +18 more
TL;DR: The PRECIOUS study is being conducted as a multicenter, randomized, open-label Phase III study to determine if retreatment with pertuzumab is more effective than conventional treatment in HER2-positive locally advanced (LA)/metastatic breast cancer patients previously treated with pertzumab, trastuzuab and chemotherapy.
Book ChapterDOI
Advances in EGFR/HER2-directed clinical research on breast cancer
TL;DR: Important points of consideration on prognosis and choice of therapies, including HER2 gene copy number, HER2 heterogeneity, tissue biomarker, blood-based biomarkers, and HER2 mutation and its treatment could potentially play a vital role in the journey of HER2-positive breast cancer patient to achieve greater survival benefit and potentially a cure for the disease.